ESR1 and breast carcinoma: These results indicate that butyrate has the potential to be avaluable addition to existing breast cancer therapies, nonetheless, additionalstudies are needed to further understand the mechanistic underpinnings of butyrate’seffects on ERα transcriptional regulation and to optimize its potential for clinicaluse in treating breast cancer.